Evogene Statistics
Total Valuation
Evogene has a market cap or net worth of $7.57 million. The enterprise value is $16.95 million.
Important Dates
The last earnings date was Wednesday, May 21, 2025, before market open.
Earnings Date | May 21, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Evogene has 6.67 million shares outstanding. The number of shares has increased by 27.71% in one year.
Current Share Class | 6.67M |
Shares Outstanding | 6.67M |
Shares Change (YoY) | +27.71% |
Shares Change (QoQ) | +0.04% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 6.59M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 1.12 |
Forward PS | 0.79 |
PB Ratio | 0.61 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 2.50 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.21.
Current Ratio | 1.06 |
Quick Ratio | 0.84 |
Debt / Equity | 0.21 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -63.07 |
Financial Efficiency
Return on equity (ROE) is -91.05% and return on invested capital (ROIC) is -68.80%.
Return on Equity (ROE) | -91.05% |
Return on Assets (ROA) | -35.10% |
Return on Invested Capital (ROIC) | -68.80% |
Return on Capital Employed (ROCE) | -121.73% |
Revenue Per Employee | $57,821 |
Profits Per Employee | -$129,991 |
Employee Count | 117 |
Asset Turnover | 0.17 |
Inventory Turnover | 2.78 |
Taxes
In the past 12 months, Evogene has paid $9,000 in taxes.
Income Tax | 9,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.31% in the last 52 weeks. The beta is 1.37, so Evogene's price volatility has been higher than the market average.
Beta (5Y) | 1.37 |
52-Week Price Change | -84.31% |
50-Day Moving Average | 1.15 |
200-Day Moving Average | 1.80 |
Relative Strength Index (RSI) | 42.46 |
Average Volume (20 Days) | 40,780 |
Short Selling Information
Short Interest | 177,981 |
Short Previous Month | 241,184 |
Short % of Shares Out | 2.67% |
Short % of Float | n/a |
Short Ratio (days to cover) | 0.18 |
Income Statement
In the last 12 months, Evogene had revenue of $6.77 million and -$15.21 million in losses. Loss per share was -$2.48.
Revenue | 6.77M |
Gross Profit | 2.78M |
Operating Income | -22.77M |
Pretax Income | -21.46M |
Net Income | -15.21M |
EBITDA | -21.15M |
EBIT | -22.77M |
Loss Per Share | -$2.48 |
Full Income Statement Balance Sheet
The company has $9.85 million in cash and $2.59 million in debt, giving a net cash position of $7.26 million or $1.09 per share.
Cash & Cash Equivalents | 9.85M |
Total Debt | 2.59M |
Net Cash | 7.26M |
Net Cash Per Share | $1.09 |
Equity (Book Value) | 12.40M |
Book Value Per Share | -0.55 |
Working Capital | 902,000 |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$20.77 million and capital expenditures -$607,000, giving a free cash flow of -$21.38 million.
Operating Cash Flow | -20.77M |
Capital Expenditures | -607,000 |
Free Cash Flow | -21.38M |
FCF Per Share | -$3.20 |
Full Cash Flow Statement Margins
Gross margin is 41.06%, with operating and profit margins of -336.57% and -224.82%.
Gross Margin | 41.06% |
Operating Margin | -336.57% |
Pretax Margin | -254.09% |
Profit Margin | -224.82% |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Evogene does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -27.71% |
Shareholder Yield | -27.71% |
Earnings Yield | -200.84% |
FCF Yield | -282.32% |
Analyst Forecast
The average price target for Evogene is $3.50, which is 218.18% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $3.50 |
Price Target Difference | 218.18% |
Analyst Consensus | Strong Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
The last stock split was on July 25, 2024. It was a reverse split with a ratio of 0.1:1.
Last Split Date | Jul 25, 2024 |
Split Type | Reverse |
Split Ratio | 0.1:1 |
Scores
Evogene has an Altman Z-Score of -12.72. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -12.72 |
Piotroski F-Score | n/a |